3,098 reports of this reaction
2.4% of all LAMOTRIGINE CHEWABLE DISPERSIBLE reports
#5 most reported adverse reaction
DRUG INTERACTION is the #5 most commonly reported adverse reaction for LAMOTRIGINE CHEWABLE DISPERSIBLE, manufactured by Alembic Pharmaceuticals Limited. There are 3,098 FDA adverse event reports linking LAMOTRIGINE CHEWABLE DISPERSIBLE to DRUG INTERACTION. This represents approximately 2.4% of all 130,108 adverse event reports for this drug.
Patients taking LAMOTRIGINE CHEWABLE DISPERSIBLE who experience drug interaction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INTERACTION is a less commonly reported adverse event for LAMOTRIGINE CHEWABLE DISPERSIBLE, but still significant enough to appear in the safety profile.
In addition to drug interaction, the following adverse reactions have been reported for LAMOTRIGINE CHEWABLE DISPERSIBLE:
The following drugs have also been linked to drug interaction in FDA adverse event reports:
DRUG INTERACTION has been reported as an adverse event in 3,098 FDA reports for LAMOTRIGINE CHEWABLE DISPERSIBLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INTERACTION accounts for approximately 2.4% of all adverse event reports for LAMOTRIGINE CHEWABLE DISPERSIBLE, making it a notable side effect.
If you experience drug interaction while taking LAMOTRIGINE CHEWABLE DISPERSIBLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.